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Unfortunately, the online published article has error in Table 5. The correct Table [5](#Tab5){ref-type="table"} is given here. The original article has been corrected.Table 5Docetaxel, CDDP, and 5-Fu for advanced esophageal cancerReferences (first author)TargetRegimen (/m^2^)PhaseCases, *n*Grade 3/4 leukopenia (%)Grade 3/4 neutropenia (%)Febrile neutropenia (%)Response rate (%)Histopathological response rate (\>grade 2) (%)Histopathological complete response rate (grade 3) (%)Dose reduction rate in the second cycle (%)Protocol completion rate (%)Takahashi \[32\]Esophageal cancer (SCC)\
Stages III, IVD: 50 (day 1)\
C: 70 (day 1)\
F: 700 (days 1--5)/3 wksI/II3953.843.612.866.6--------Osaka \[33\]Esophageal cancer (SCC)\
Stages III, IVD: 60 (day 1)\
C: 60 (day 1)\
F: 800 (days 1--5)/3--4 wks × 2 coursesII3033.3----83.3 (primary lesion)------96.7Yamasaki \[23\]Esophageal cancer (SCC)\
Stages III, IVD: 70 (day 1)\
C: 70 (day 1)\
F: 700 (days 1--5)/3 wks × 2 coursesI/II9/4072.5901072.54025--82.5Tamura \[34\]Esophageal cancer (SCC)\
Stage IVD: 60 (day 1)\
C: 70 (day 1)\
F: 600 (days 1--5)/4 wks × 2 coursesII2952762134.5 (confirmed cases)----13.8--Ferri \[35\]Esophageal cancer and gastric cancer (AD)\
Stages II, III, IVD: 75 (day 1)\
C: 75 (day 1)\
F: 750 (days 1--5)/3 wks × 3 coursesII43--202.3----9.8--95Hara \[36\]Esophageal cancer (SCC)\
Stages IIA, IIB, IIID: 70 (day 1)\
C: 70 (day 1)\
F: 750 (days 1--5)\
D: 75 (day 1)\
C: 75 (day 1)\
F: 750 (days 1--5)/3 wks × 3 coursesII4245.283.32.464.3511764.395.2Watanabe \[37\]Esophageal cancer (SCC, AD)\
Stages IIB, III, IVA, IVB (TNM6)D: 60 (day 1)\
C:6 (days 1--5)\
F: 350 (days 1--5)/3 wks × 2 coursesProspective intension-to-treat50--78.214.553.72612----Hironaka \[38\]Esophageal cancer (SCC, AS, B)\
Stage IVD: 30 (days 1, 15)\
C: 80 (day 1)\
F: 800 (days 1--5)/4 wksI/II10/529.125.5062--------Current studyEsophageal cancer (SCC)\
Stages II, IIID: 35 (days 1, 15)\
C:40 (days 1, 15)\
F: 400 (days 1--5, 15--19)II3212.531.3090.353.221.90100*SCC* squamous cell carcinoma, *AD* adenocarcinoma, *AS* adenosquamous carcinoma, *B* basaloid carcinoma, *D* docetaxel, *C* cisplatin, *F* fluorouracil
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